Literature DB >> 18568889

Dexamethasone increases pigment epithelium-derived factor in perfused human eyes.

Elizabeth M Perruccio1, Laura Leigh S Rowlette, Nuria Comes, Silvia Locatelli-Hoops, Luigi Notari, S Patricia Becerra, Teresa Borrás.   

Abstract

PURPOSE: To investigate the effects of dexamethasone (DEX) on pigment epithelium-derived factor (PEDF) cDNA and secreted protein in human trabecular meshwork (TM).
METHODS: Anterior segment organ cultures were perfused with 0.1 microM DEX (OD) and vehicle (OS). Primary human TM cells (HTM) were treated with DEX under similar conditions. PEDF mRNA and secreted PEDF protein were quantitated by RT-PCR and Western blot.
RESULTS: PEDF mRNA and secreted PEDF protein levels were significantly higher in DEX over vehicle-treated cultures. In contrast, DEX decreased the activity of a 92-kDa gelatinolytic zymogen in organ culture effluents.
CONCLUSION: DEX action in the human TM might include a PEDF-mediating pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568889      PMCID: PMC2720275          DOI: 10.1080/02713680802110208

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  18 in total

1.  Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone.

Authors:  Y el-Shabrawi; M Eckhardt; A Berghold; J Faulborn; L Auboeck; H Mangge; N Ardjomand
Journal:  Eye (Lond)       Date:  2000-06       Impact factor: 3.775

2.  The association of single nucleotide polymorphisms in the MMP-9 genes with susceptibility to acute primary angle closure glaucoma in Taiwanese patients.

Authors:  I-Jong Wang; Ting-Hsuan Chiang; Yung-Feng Shih; Shao-Chun Lu; Luke Long-Kuang Lin; Jui-Wen Shieh; Tsing-Hong Wang; John R Samples; Por-Tying Hung
Journal:  Mol Vis       Date:  2006-10-26       Impact factor: 2.367

Review 3.  Focus on Molecules: Pigment epithelium-derived factor (PEDF).

Authors:  S Patricia Becerra
Journal:  Exp Eye Res       Date:  2005-12-20       Impact factor: 3.467

4.  Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia.

Authors:  Luigi Notari; Amanda Miller; Alfredo Martínez; Juan Amaral; Meihua Ju; Gregory Robinson; Lois E H Smith; S Patricia Becerra
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-08       Impact factor: 4.799

5.  Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor.

Authors:  E Alberdi; M S Aymerich; S P Becerra
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

6.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

7.  Effects of elevated intraocular pressure on outflow facility and TIGR/MYOC expression in perfused human anterior segments.

Authors:  Teresa Borrás; Laura Leigh S Rowlette; Ernst R Tamm; Johannes Gottanka; David L Epstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-01       Impact factor: 4.799

8.  Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma.

Authors:  Wayne R Lo; Laura Leigh Rowlette; Montserrat Caballero; Ping Yang; M Rosario Hernandez; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-02       Impact factor: 4.799

9.  Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients.

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Rong Liu; Heike Mönkemann; David Leppert; Hans Schild; Ivan O Haefliger; Josef Flammer
Journal:  J Glaucoma       Date:  2004-02       Impact factor: 2.503

10.  Involvement of the Erk-MAP kinase pathway in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs.

Authors:  J Preston Alexander; Ted S Acott
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-01       Impact factor: 4.799

View more
  6 in total

1.  Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys.

Authors:  LaKisha K Buie; Carol A Rasmussen; Eric C Porterfield; Vinod S Ramgolam; Vivian W Choi; Silva Markovic-Plese; Richard J Samulski; Paul L Kaufman; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-13       Impact factor: 4.799

2.  Gene expression changes in steroid-induced IOP elevation in bovine trabecular meshwork.

Authors:  John Danias; Rosana Gerometta; Yongchao Ge; Lizhen Ren; Lampros Panagis; Thomas W Mittag; Oscar A Candia; Steven M Podos
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

Review 3.  The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential.

Authors:  S Patricia Becerra; Vicente Notario
Journal:  Nat Rev Cancer       Date:  2013-03-14       Impact factor: 60.716

4.  Pigment epithelium-derived factor decreases outflow facility.

Authors:  Morgan E Rogers; Iris D Navarro; Kristin M Perkumas; Shannon M Niere; R Rand Allingham; Craig E Crosson; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-11       Impact factor: 4.799

Review 5.  PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases.

Authors:  Xuemin He; Rui Cheng; Siribhinya Benyajati; Jian-xing Ma
Journal:  Clin Sci (Lond)       Date:  2015-06       Impact factor: 6.124

6.  PEDF expression is inhibited by insulin treatment in adipose tissue via suppressing 11β-HSD1.

Authors:  Yinli Zhou; Fen Xu; Hongrong Deng; Yan Bi; Weiping Sun; Yi Zhao; Zonglan Chen; Jianping Weng
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.